Cairo – Mubasher: The Board of Directors of Nile Pharmaceuticals and Chemical Industries has approved studying the uses of the capital increase proceeds and their expected returns, and submitting the same to the Extraordinary General Meeting for consideration.
The company stated in a filing to the Egyptian Exchange (EGX) today that the Board agreed to convene the Extraordinary General Meeting on 15 November 2026 to consider the submitted memorandum regarding the study and the proposal to increase the issued and paid-up capital from EGP 500 million to EGP 1 billion.
It added that this comes following the Financial Regulatory Authority's (FRA) approval of Disclosure Form 48 on 19 October 2026.
Furthermore, the Board approved presenting to the Ordinary General Meeting, scheduled for 31 October 2026, the proposal to appoint Nasr Abou El Abbas Ahmed & Co. (Morison Global) as the company's external auditor for the fiscal year 2026/2027.
